NewSquare Capital LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

NewSquare Capital LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 55,931 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. NewSquare Capital LLC’s holdings in Gilead Sciences were worth $5,101,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Bellevue Group AG lifted its stake in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after purchasing an additional 48,910 shares in the last quarter. McAdam LLC lifted its stake in Gilead Sciences by 16.7% in the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after purchasing an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC lifted its stake in Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock worth $13,132,000 after purchasing an additional 5,382 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 293,356 shares of company stock valued at $29,166,240 in the last quarter. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 1.1 %

Shares of GILD opened at $114.74 on Wednesday. The stock has a market capitalization of $143.00 billion, a P/E ratio of 310.11, a PEG ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a fifty day simple moving average of $98.28 and a two-hundred day simple moving average of $90.74. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $117.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.75%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Morgan Stanley increased their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $102.76.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.